SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. (SIBN) insider Anshul Maheshwari, an officer, has filed a notice to sell 11,636 shares of common stock through broker Morgan Stanley Smith Barney LLC. The proposed sale has an approximate aggregate value of $232,254.56 and is to be effected on or before 08/24/2026 on NASDAQ.
The shares to be sold were acquired upon vesting of restricted stock units (RSUs) and performance stock units (PSUs) during the period from 01/01/2025 through 02/15/2026. The notice also lists recent sales over the past three months under or associated with a Rule 10b5-1 trading plan.
SI-BONE, Inc. (SIBN) is the issuer for a planned sale of its common stock reported by the DAVID & LAURA FRANCIS JOINT REV TRU/A DTD 01/03/2003 under Rule 144. The trust has filed to sell 25,972 shares of common stock that were acquired upon vesting of restricted stock units beginning 05/15/2021.
The notice also lists recent sales over the past three months, including Rule 10b5-1 plan transactions by the trust and separate sales by Laura Francis.
SI-BONE, Inc. (SIBN) reported that a trust associated with Chief Executive Officer and director Laura Francis sold shares of Common Stock under a Rule 10b5-1 trading plan dated May 21, 2026. On August 20, 2026, the trust sold 51,884 shares at a weighted-average price of $19.46 per share, in multiple transactions ranging from $19.10 to $19.73. On August 21, 2026, it sold an additional 3,923 shares at a weighted-average price of $20.02, in trades ranging from $20.00 to $20.05. Following these transactions, Laura Francis directly holds 493,900 shares, including 355,697 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) insider Anshul Maheshwari, Chief Op & Financial Officer, reported open-market sales of company common stock under a Rule 10b5-1 trading plan dated December 17, 2025. He sold 5,747 shares on August 19, 2026 at a weighted-average price of $19.55 and 11,228 shares on August 21, 2026 at a weighted-average price of $20.02, for total reported sales of 16,975 shares. Following these transactions, his direct holdings include 167,604 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) received a notice that the DAVID & LAURA FRANCIS JOINT REVOCABLE TRUST dated 01/03/2003 intends to sell 3,923 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares have an aggregate market value of $76,420.04 based on the stated market price.
The notice indicates SI-BONE had 44,818,575 shares of common stock outstanding. The securities to be sold include 1,901 shares from Performance Stock Units and 2,022 shares from Restricted Stock Units. In the past three months, the trust and Laura Francis reported prior Rule 10b5-1-related and other sales of common stock.
SI-BONE, Inc. (SIBN) insider Anshul Maheshwari filed a notice of proposed sale of company common stock under Rule 144. The notice covers 11,228 shares of common stock, with an indicated aggregate market value of $218,721.44. The shares were acquired upon vesting of restricted stock units and performance stock units during the period from 01/01/2025 through 02/15/2026. Prior sales under a 10b5-1 trading plan over the past three months totaled several thousand shares of SI-BONE common stock.
SI-BONE, Inc. (SIBN) has a notice of proposed sale of securities under Rule 144 filed for the account of the David & Laura Francis Joint Revocable Trust. The trust plans to sell up to 51,884 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,033,010.44 and with 44,818,575 shares outstanding as referenced in the notice. The shares were acquired upon vesting of restricted stock units between 05/15/2021 and 11/15/2025. The filing also notes a prior sale by Laura Francis in the past three months of 14,956 shares of common stock for $279,064.67.
SI-BONE, Inc. (SIBN) has an affiliate, Anshul Maheshwari, providing notice of a planned resale of company stock under Rule 144. The notice covers up to 5,747 shares of SI-BONE common stock, to be sold through Morgan Stanley Smith Barney LLC on or after August 19, 2026.
The shares were acquired upon vesting of restricted stock units during the period from April 1, 2026 through August 15, 2026. The form also lists prior sales by Maheshwari in the last three months, reflecting additional Rule 144 activity in SI-BONE shares.
SI-BONE, Inc. (SIBN) disclosed that Chief Executive Officer Laura Francis reported multiple same‑day open‑market sales totaling 14,956 shares of common stock on 2026-08-17 at weighted average prices around $18.63–$18.68 per share. Footnotes state these were "sell to cover" transactions executed to satisfy tax withholding obligations upon the vesting of restricted stock units and are not discretionary trades. After these trades, 373,270 shares are held indirectly by The David & Laura Joint Rev Tr., and an additional 355,697 shares are issuable upon settlement of restricted stock units granted to the reporting person.
SI-BONE, Inc. (SIBN) officer Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer, reported selling a total of 3,725 shares of common stock on August 17, 2026, in open-market transactions. According to the disclosure, these sales were required solely to cover tax withholding obligations from vesting restricted stock units under a “sell to cover” arrangement and did not represent discretionary trades. Following these transactions, Pisetsky’s reported holdings include 130,281 shares issuable upon settlement of restricted stock units, each unit representing a contingent right to one share of SI-BONE common stock.